Research Analysts Offer Predictions for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research increased their FY2025 earnings estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $6.01 per share for the year, up from their previous forecast of $5.91. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.86 EPS, Q1 2026 earnings at $1.42 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $2.38 EPS, FY2026 earnings at $7.43 EPS, Q2 2027 earnings at $2.02 EPS, Q3 2027 earnings at $1.99 EPS, Q4 2027 earnings at $2.54 EPS and FY2027 earnings at $8.18 EPS.

HALO has been the subject of several other research reports. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a research report on Tuesday, October 14th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. TD Cowen increased their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $77.93 on Wednesday. Halozyme Therapeutics has a 1 year low of $47.50 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a fifty day moving average price of $69.12 and a two-hundred day moving average price of $68.84. The firm has a market cap of $9.16 billion, a P/E ratio of 16.41, a PEG ratio of 0.32 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the firm earned $1.27 EPS. Halozyme Therapeutics’s revenue was up 22.1% on a year-over-year basis.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 41,398 shares of company stock valued at $2,861,352. 2.40% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Moran Wealth Management LLC boosted its position in shares of Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares in the last quarter. Campbell Newman Asset Management Inc. lifted its holdings in Halozyme Therapeutics by 0.4% during the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after acquiring an additional 153 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 165 shares during the period. Alps Advisors Inc. increased its holdings in shares of Halozyme Therapeutics by 3.0% in the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 170 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple quarterly and annual EPS forecasts (notably FY2026 to $7.43 from $6.22 and FY2027 to $8.18 from $7.57), reflecting stronger forward profit expectations that can support a higher valuation. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Zacks also lifted several near‑term quarter estimates (Q1–Q4 2026 and multiple quarters in 2027), signalling anticipated stronger revenue/earnings momentum that likely helped investor sentiment. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Coverage highlighting Halozyme as an attractive long‑term/value investment (Zacks style score write‑up) bolsters the buy case for value‑oriented investors. Why Halozyme is a Top Value Stock (Zacks)
• Positive Sentiment: An investor piece arguing that recent acquisitions position Halozyme for longer‑term growth supports the strategic narrative beyond near‑term numbers and may attract growth investors. Halozyme: Key Acquisitions (Seeking Alpha)
• Neutral Sentiment: Zacks’ reports reiterate a wide range of forward estimates — consensus figures cited in summaries differ from Zacks’ own upgraded forecasts — so investors should watch upcoming company disclosures for confirmation. MarketBeat: HALO coverage
• Negative Sentiment: One small downgrade: Zacks trimmed Q3 2027 EPS slightly (from $2.02 to $1.99) — a minor data point but a reminder that not every quarter was raised. MarketBeat: HALO coverage

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.